208 related articles for article (PubMed ID: 37516994)
21. Aggressive Pituitary Adenomas: The Dark Side of the Moon.
Priola SM; Esposito F; Cannavò S; Conti A; Abbritti RV; Barresi V; Baldari S; Ferraù F; Germanò A; Tomasello F; Angileri FF
World Neurosurg; 2017 Jan; 97():140-155. PubMed ID: 27713064
[TBL] [Abstract][Full Text] [Related]
22. Refractory pituitary adenoma: a novel classification for pituitary tumors.
Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
[TBL] [Abstract][Full Text] [Related]
23. Pituitary carcinoma - case series and review of the literature.
Du Four S; Van Der Veken J; Duerinck J; Vermeulen E; Andreescu CE; Bruneau M; Neyns B; Velthoven V; Velkeniers B
Front Endocrinol (Lausanne); 2022; 13():968692. PubMed ID: 36157469
[TBL] [Abstract][Full Text] [Related]
24. How and when to use temozolomide to treat aggressive pituitary tumours.
Whitelaw BC
Endocr Relat Cancer; 2019 Aug; 26(9):R545-R552. PubMed ID: 31311005
[TBL] [Abstract][Full Text] [Related]
25. Aggressive pituitary tumors.
Chatzellis E; Alexandraki KI; Androulakis II; Kaltsas G
Neuroendocrinology; 2015; 101(2):87-104. PubMed ID: 25571935
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
[TBL] [Abstract][Full Text] [Related]
28. Aggressive corticotroph tumors and carcinomas.
Lasolle H; Vasiljevic A; Jouanneau E; Ilie MD; Raverot G
J Neuroendocrinol; 2022 Aug; 34(8):e13169. PubMed ID: 35979732
[TBL] [Abstract][Full Text] [Related]
29. Aggressive prolactinomas: how to manage?
Lasolle H; Ilie MD; Raverot G
Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
[TBL] [Abstract][Full Text] [Related]
30. Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report.
Shah S; Manzoor S; Rothman Y; Hagen M; Pater L; Golnik K; Mahammedi A; Lin AL; Bhabhra R; Forbes JA; Sengupta S
Neurosurgery; 2022 Aug; 91(2):e51-e56. PubMed ID: 35544035
[TBL] [Abstract][Full Text] [Related]
31. Therapy of aggressive pituitary tumors.
Colao A; Grasso LF; Pivonello R; Lombardi G
Expert Opin Pharmacother; 2011 Jul; 12(10):1561-70. PubMed ID: 21434849
[TBL] [Abstract][Full Text] [Related]
32. Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.
Kamiya-Matsuoka C; Cachia D; Waguespack SG; Crane CH; Mahajan A; Brown PD; Nam JY; McCutcheon IE; Penas-Prado M
Pituitary; 2016 Aug; 19(4):415-21. PubMed ID: 27106209
[TBL] [Abstract][Full Text] [Related]
33. Multimodal therapy in aggressive pituitary tumors.
Iglesias P; Magallón R; Mitjavila M; Rodríguez Berrocal V; Pian H; Díez JJ
Endocrinol Diabetes Nutr (Engl Ed); 2020; 67(7):469-485. PubMed ID: 31740190
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Lamas C; Cámara R; Fajardo C; Remon-Ruiz P; Biagetti B; Guerrero-Pérez F; Araujo-Castro M; Mora M; Hanzu F; Iglesias P; García-Centeno R; Soto A
Front Endocrinol (Lausanne); 2023; 14():1204206. PubMed ID: 37720528
[TBL] [Abstract][Full Text] [Related]
35. The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs).
Yavropoulou MP; Tsoli M; Barkas K; Kaltsas G; Grossman A
Endocr Relat Cancer; 2020 Oct; 27(10):R375-R390. PubMed ID: 32674070
[TBL] [Abstract][Full Text] [Related]
36. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.
Raverot G; Castinetti F; Jouanneau E; Morange I; Figarella-Branger D; Dufour H; Trouillas J; Brue T
Clin Endocrinol (Oxf); 2012 Jun; 76(6):769-75. PubMed ID: 22404748
[TBL] [Abstract][Full Text] [Related]
37. Multimodality treatment for invasive pituitary adenomas.
Hornyak M; Couldwell WT
Postgrad Med; 2009 Mar; 121(2):168-76. PubMed ID: 19332975
[TBL] [Abstract][Full Text] [Related]
38. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently.
Bradley KJ; Wass JA; Turner HE
Clin Endocrinol (Oxf); 2003 Jan; 58(1):59-64. PubMed ID: 12519413
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab in Aggressive Pituitary Adenomas - Experience with 3 Patients.
Osterhage K; Rotermund R; Droste M; Dierlamm J; Saeger W; Petersenn S; Aberle J; Flitsch J
Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):178-185. PubMed ID: 33285600
[TBL] [Abstract][Full Text] [Related]
40. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
